Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious known stimulus. Drug treatment is largely dominated by antihistamines. However, one biologic, Novartis / Roche’s Xolair, is approved for chronic idiopathic urticaria; clinical guidelines recommend it as a third-line treatment. Xolair’s dominance demonstrates that opportunity remains in the CSU market for other biologics in development. In addition, montelukast is a key drug in the CSU market and a preferred combination agent, consistent with the recommended use of leukotriene receptor antagonists as add-on treatment in the current urticaria treatment guidelines.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.